Key result
Syringin attenuates doxorubicin-induced cardiotoxicity and myocardial atrophy via APJ/PI3K/AKT and NRF2/HO-1 antioxidant pathways.
Why the study?
Doxorubicin-induced cardiotoxicity mediated by oxidative stress is a major clinical challenge, and the efficacy and mechanism of syringin in this setting remain poorly defined.
Does Syringin prevent Doxorubicin-induced cardiotoxicity in a mouse model and primary cardiomyocytes?
Population
Doxorubicin-induced mouse model of cardiotoxicity and primary cardiomyocytes
Comparison
Syringin vs pravastatin (10 mg/kg) positive control and controls
Design
Preclinical animal and cellular experimental study
Authors
Loading...
Should not yet change cardio-oncology practice; extends preclinical evidence for APJ-targeted therapy in doxorubicin cardiotoxicity.
Does Syringin prevent Doxorubicin-induced cardiotoxicity in a mouse model and primary cardiomyocytes?
Syringin is a promising natural compound for mitigating chemotherapy-induced cardiotoxicity by targeting the APJ receptor pathway.
Li et al. (2026) studied this question. Syringin significantly attenuates doxorubicin-induced cardiotoxicity, myocardial atrophy, and oxidative stress by activating the APJ/PI3K/AKT and NRF2/HO-1 antioxidant signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: